MALIGNANT SOLID TUMOURS Clinical Trials

14 clinical trials for MALIGNANT SOLID TUMOURS across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A FIRST-IN-HUMAN PHASE I, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER DOSE ESCALATION TRIAL OF BI 765049 AND BI 765049 + EZABENLIMAB ADMINISTERED BY REPEATED INTRAVENOUS INFUSIONS IN PATIENTS WITH MALIGNANT SOLID TUMORS EXPRESSING B7-H6 — RECRUITING · PHASE1
• AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) — RECRUITING · PHASE2
• A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES — RECRUITING
• AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) -- CORE PROTOCOL — RECRUITING
• A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABLITY AND PHARMACOKINETICS OF AB-16B5 IN SUBJECTS WITH AN ADVANCED SOLID MALIGNANCY. — RECRUITING · PHASE1
• A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES — RECRUITING · PHASE1
• "A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS-22M6E GIVEN AS MONOTHERAPY FOLLOWED BY EXPANSION COHORTS IN SUBJECTS WITH MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4." — RECRUITING · PHASE1
• Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors — OTHER · PHASE1
• A PHASE I, OPEN-LABEL STUDY OF GSK1795091 ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPIES IN PARTICIPANTS WITH ADVANCED SOLID TUMORS — COMPLETED · PHASE1
• PHASE I OPEN LABEL, DOSE ESCALATION TRIAL TO DETERMINE THE MTD, SAFETY, PK AND EFFICACY OF AFATINIB MONOTHERAPY IN CHILDREN AGED 2 YEARS TO <18 YEARS WITH RECURRENT/REFRACTORY NEUROECTODERMAL TUMOURS, RHABDOMYOSARCOMA AND/OR OTHER SOLID TUMOURS WITH KNOWN ERBB PATHWAY DEREGULATION REGARDLESS OF TUMOUR HISTOLOGY — COMPLETED · PHASE1
• A PHASE 1A, MULTI-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY TO ASSESS THE SAFETY, BIODISTRIBUTION AND TUMOUR UPTAKE OF [I-124]-CPD-1028 INJECTION — NOT_YET_RECRUITING · PHASE1
• A PHASE I, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF ASCENDING DOSES OF AZD5363 UNDER ADAPTABLE DOSING SCHEDULES IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES — COMPLETED · PHASE1
• A PHASE I, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF ASCENDING DOSES OF AZD8186 IN PATIENTS WITH ADVANCED CASTRATE-RESISTANT PROSTATE CANCER (CRPC), SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC), TRIPLE NEGATIVE BREAST CANCER (TNBC) AND PATIENTS WITH KNOWN PTEN-DEFICIENT ADVANCED SOLID MALIGNANCIES, WITH EXPANSION TO ASSESS THE PHARMACODYNAMIC ACTIVITY OF AZD8186 WITHIN PROSPECTIVELY-VALIDATED PTEN DEFICIENT TUMOURS — COMPLETED · PHASE1
• PDM08 Clinical Trial in Advanced Solid Tumors — COMPLETED · PHASE1

Refine this search